Emergent BioSolutions, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Emergent BioSolutions, Inc.
From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.
Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.
US FDA oversees plants straining to meet demand for COVID-19 vaccines and treatments, while cracking down on adulterated hand sanitizers.
France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Adapt Pharma Limited
- Aptevo Therapeutics
- BioPort Corporation
- Cangene Corporation
- Trubion Pharmaceuticals, Inc.
- PaxVax Corporation